Document:

EX-10.49

 Exhibit 10.49 

INVOLUNTARY TERMINATION AGREEMENT 

THIS INVOLUNTARY TERMINATION AGREEMENT (this “Agreement”) is entered into effective as of January 13, 2020 (the
“Effective Date”), by and between RTI Surgical Holdings, Inc., a Delaware corporation (the “Company”), and Olivier Visa (the “Executive”). 

1. Definitions. As used in this Agreement, the following terms have the respective meanings set forth below: 

(a) “Accrued Obligations” means the sum of the following payments accrued by the Executive as of the Termination Date, to the
extent not yet paid: (i) base salary, to the extent earned; (ii) any bonus, annual incentive compensation, deferred compensation, and other cash compensation, to the extent earned; and (iii) any vacation pay, expense reimbursements,
and other cash entitlements. 
 (b) “Affiliate” means any corporation or other entity (i) in which the Company has a
direct or indirect ownership interest of 50% or more of the total combined voting power of the then-outstanding securities of such corporation or other entity entitled to vote generally in the election of directors or (ii) that has a direct or
indirect ownership interest of 50% or more of the total combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors. 

(c) “Board” means the Board of Directors of the Company. 

(d) “Cause” means the occurrence of any of the following events, unless, to the extent remedy is reasonably feasible, such
event is fully remedied by the Executive in all material respects within 15 days after the Company provides written notification of the occurrence of such event to the Executive: 

(i) the Executive’s willful misconduct or gross negligence in the performance of the Executive’s material duties to the Company;

 (ii) the Executive’s failure to perform the Executive’s material duties to the Company or to follow the lawful directives of
the Board or the officer to whom the Executive reports (other than as a result of death or disability); 
 (iii) indictment or conviction
of the Executive, or pleading by the Executive of guilty or nolo contendere to, any felony or any crime involving moral turpitude; 
 (iv)
the Executive’s violation of any laws, rules or regulations of any governmental or regulatory body, which violation is or is reasonably likely to be materially injurious to the Company’s financial condition or reputation; 

(v) the Executive’s failure to cooperate in any audit or investigation of the business or financial practices of the Company or any of
its subsidiaries; 
 (vi) the Executive’s performance of any act of theft, embezzlement, fraud, material malfeasance, material
dishonesty or misappropriation of the Company’s property; 

 (vii) breach by the Executive of a provision of this Agreement or any agreement with the
Company, or a violation by the Executive of the Company’s code of conduct or any other written policy, which breach or violation is or is reasonably likely to be materially injurious to the Company’s financial condition or reputation; 

(viii) the Executive’s possession or use of illegal drugs; 

(ix) the Executive’s legal use of alcohol or controlled substances in a manner that materially impairs the Employee’s ability to
effectively perform his job; or 
 (x) the Executive’s commission of any act that is or is reasonably likely to be materially
injurious to the Company’s financial condition or reputation. 
 The Company shall provide the Executive with a written notice detailing the specific
circumstances alleged to constitute Cause within 30 days after the Company becomes aware of such circumstances, and may terminate the Executive’s employment within 10 days following the expiration of the Executive’s 15-day cure period described above, to the extent remedy is reasonably feasible. 
 (e)
“Code” means the Internal Revenue Code of 1986, as amended. 
 (f) “Good Reason” means, without the
written consent of the Executive, the occurrence of any one or more of the following: 
 (i) a material reduction of the Executive’s
base salary or target annual bonus; 
 (ii) a material diminution in the Executive’s position, duties, authority, or responsibilities
(other than temporarily while the Executive is physically or mentally incapacitated); 
 (iii) a relocation of the Executive’s primary
place of employment by more than 60 miles; or 
 (iv) the Company’s material breach of this Agreement or any agreement between the
Company and the Executive. 
 Notwithstanding the foregoing, no condition may constitute Good Reason unless (A) the Executive provides written notice
to the Company of the existence of such condition no later than 60 days after the Executive knows or reasonably should know of the existence of such condition, (B) the Company fails to remedy such condition within 30 days after receipt of such
notice, and (C) the Executive resigns due to the existence of such condition within 60 days after the expiration of the remedial period described in clause (B). 

(g) “Involuntary Termination” means termination of the Executive’s employment by the Company without Cause or the
Executive’s resignation for Good Reason. 

  
 2 

 (h) “Sale” means the consummation of the sale, in one or more transactions,
of either: (i) a majority of the then-outstanding capital stock or equity interests of all of the Subsidiaries of the Company that own at least 80% of the assets that are used in or comprise the Company’s OEM business or (ii) at least
80% of the assets owned by the Company and its Subsidiaries that are used in or comprise the Company’s OEM business; provided, however, for the avoidance of doubt, any sale of all or substantially all of the Assets of the Company or any
transaction (whether a merger, reorganization, statutory share exchange, consolidation or similar transaction (collectively, a “Business Combination”)) which results in the transfer of a majority of the voting power of the Company to
persons or entities which were not in control of the Company prior to the Business Combination, shall be deemed a Sale. 
 (i)
“Subsidiary” means, with respect to the Company, any corporation, limited liability company, partnership or other business entity: (i) of which 50% or more of any class of capital stock or other equity interest is owned or
controlled, directly or indirectly, by the Company; or (ii) of which the Company is a general partner. 
 (j) “Termination
Date” means (i) the date of the Executive’s separation from service, within the meaning of the Code, or (ii) if the Executive’s employment by the Company terminates by reason of death, the date of death, or disability,
the date of disability. 
 (k) “Transition Period” means the period beginning on the closing date of a Sale and ending six
months after a Sale. 
 2. Term. This Agreement will remain in effect for a two-year term
beginning as of the Effective Date (the “Term”) unless either the Company or the Executive provides notice of termination of the Agreement to the other at least 90 days prior to the expiration of the Term; provided that no such
early termination has the effect of reducing or diminishing the rights of the Executive under this Agreement without the written consent of the Executive. 

3. General Severance Terms. 

(a) In exchange for the rights granted to the Executive under this Agreement, the Executive unconditionally and irrevocably waives any rights
and benefits that may be applicable to him or her under any policy of the Company related to the termination of the Executive’s employment with the Company, unless a Sale does not occur (in which case any Company policy then in place should be
applicable to the Executive). 
 (b) If the Executive breaches in any material respect any restrictive covenants in any agreement between
the Executive and the Company or any of its Affiliates, including any non-competition, non-solicitation, non-disparagement, or
confidentiality covenant (the “Restrictive Covenants”), and fails to remedy such breach within 30 days after receipt of written notice of such breach from the Company, (i) the Executive’s entitlement to the payments and
benefits set forth in Section 4 shall be null and void; (ii) all rights to receive or continue to receive severance payments and benefits will cease; and (iii) the Executive must immediately repay to the Company all amounts already
paid to, and the value of all benefits already received by, the Executive pursuant to Section 4. The foregoing does not limit any other rights or remedies the Company may have existing in its favor, including injunctive relief. 

  
 3 

 (c) If the Executive’s employment with the Company terminates for any reason, the
Company shall pay the Executive all Accrued Obligations within 15 days following the Termination Date (except to the extent payment of such Accrued Obligation is required to be paid later pursuant to the terms of an applicable plan or agreement),
regardless of whether the Executive complies with the Release Requirement (as defined below) or the Restrictive Covenants. 
 (d) In the
event of a Sale, the vesting of the Executive’s equity awards shall accelerate. 
 4. Payments upon an Involuntary Termination in
Connection with a Sale. In the event of an Involuntary Termination during the Transition Period, and provided the Executive executes and has not revoked a general release agreement in a form prescribed by the Company within 30 days after the
Termination Date (the “Release Requirement”), the Company will provide the Executive with an amount equal to 12 times the Executive’s monthly base salary as of the Termination Date, payable, at the Company’s option,
either: (i) in substantially equal installments on the Company’s regularly scheduled payroll dates over a 12-month period, and commencing within 30 days after the Termination Date; or (ii) in a
lump sum within 30 days following the Termination Date; provided that if the Sale does not constitute a “change in control event,” within the meaning of Section 409A of the Code, then any portion of the payment to be made pursuant to
this Section 4 that is considered deferred compensation, within the meaning of Section 409A of the Code, shall be paid in accordance with clause (i) of this Section 4, to the extent required by Section 409A of the Code. 

5. Other Termination of Employment. If the employment of the Executive terminates for any reason other than an Involuntary Termination,
then the Executive will receive payment of only the Accrued Obligations. 
 6. Section 280G. To the extent that any payment or
distribution to or for the benefit of the Executive pursuant to the terms of this Agreement or any other plan, arrangement, or agreement with the Company, any of its affiliated companies, any person whose actions result in a change of ownership or
effective control covered by Section 280G(b)(2) of the Code, or any person affiliated with the Company or such person, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (the
“Payments”), would be subject to the excise tax (the “Excise Tax”) imposed by Section 4999 of the Code, then the Company will reduce the payments to the amount that is (after taking into account federal, state,
local, and social security taxes at the maximum marginal rates, and including any excise taxes imposed by Section 4999 of the Code) one dollar less than the amount of the Payments that would subject the Executive to the Excise Tax (the
“Safe Harbor Cap”). 
 7. Withholding Taxes. The Company may withhold from all payments due to the Executive (or the
Executive’s beneficiary or estate) hereunder all taxes that, by applicable federal, state, local, or other law, the Company is required to withhold therefrom. The Company may also reduce the amounts otherwise payable pursuant to this Agreement
to satisfy the Executive’s required contributions for the health coverage being provided hereunder. 

  
 4 

 8. Amendment and Waiver. No provision of this Agreement may be amended, modified, or
waived unless such amendment, modification, or waiver is agreed to in writing and signed by the Executive and by a duly authorized officer of the Company; provided that the Company may amend the Agreement in a manner that is beneficial to the
interests of the Executive without the Executive’s written consent. No waiver by any party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such
other party will be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. Failure by the Executive or the Company to insist upon strict compliance with any provision of this Agreement or to
assert any right the Executive or the Company may have hereunder will not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement. Except as otherwise expressly set forth in this Agreement or in any
agreement with respect to any equity ownership interest in the Company owned by the Executive, the rights of, and benefits payable to, the Executive pursuant to this Agreement are in addition to any rights against, or benefits payable by, third
parties (i.e., persons other than the Company or any of its Affiliates), to the Executive under any other employee benefit plan or program of the Company. 

9. Scope of Agreement. Nothing in this Agreement entitles the Executive to continued employment with the Company or its subsidiaries or
any of their respective Affiliates. Any amounts paid pursuant to this Agreement are in lieu of any other amounts of severance relating to salary, incentive or other bonus compensation, or equity compensation to be received by the Executive from the
Company or its Affiliates upon termination of employment of the Executive under any employment, employee benefit, equity compensation, or severance plan or agreement, policy, or similar arrangement of the Company or its Affiliates in effect as of
the date hereof; provided that nothing in this Section 9 affects the Executive’s rights with respect to any equity ownership interest in the Company. If the Company or any of its Affiliates are obligated by law to pay severance pay, notice
pay, or similar benefits, or if the Company or any of its Affiliates are obligated by law to provide advance notice of separation (“Notice Period”), then the payments made under this Agreement will be reduced by the amount of any
such severance, notice pay, or similar benefits, as applicable, and by the amount of any severance pay, notice pay, or similar benefits received during any Notice Period. 

10. Successors; Binding Agreement. 

(a) This Agreement will not terminate upon any merger or consolidation of the Company, whether or not the Company is the surviving or
resulting corporation, as a result of any transfer or sale of all or substantially all of the assets of the Company, or as a result of a Sale. In the event of any such merger, consolidation, transfer or sale of assets, or Sale, the provisions of
this Agreement will be binding upon the surviving or resulting corporation or the person or entity to which such assets are transferred. 

(b) This Agreement shall be binding upon and inure to the benefit of the parties named in this Agreement and their respective successors and
permitted assigns. No party may assign either this Agreement or any of its rights, interests, or obligations under this 

  
 5 

 
Agreement; provided, however, that the Company may assign this Agreement to any successor, purchaser of all or substantially all of the assets of the Company, or purchaser in connection with a
Sale. Any attempted assignment of this Agreement or any rights, interests, or obligations under this Agreement not in accordance with the terms of this Section 10(b) shall be void. 

11. Section 409A Compliance. This Agreement is intended to comply with the requirements of Section 409A of the Code, and shall be
interpreted and construed consistently with such intent. The payments to the Executive pursuant to this Agreement are also intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay
exemption pursuant to Treasury regulation §1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury regulation §1.409A-1(b)(4), and for such
purposes, each payment to the Executive under this Agreement shall be considered a separate payment. In the event the teens of this Agreement would subject the Executive to taxes or penalties under Section 409A of the Code (“409A
Penalties”), the Company and the Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible; provided that in no event shall the Company be responsible for any 409A Penalties
that arise in connection with any amounts payable under this Agreement. To the extent any amounts under this Agreement are payable by reference to the Executive’s “termination of employment,” such term and similar terms shall be
deemed to refer to the Executive’s “separation from service,” within the meaning of Section 409A of the Code. Notwithstanding any other provision in this Agreement, to the extent any payment hereunder constitutes nonqualified
deferred compensation, within the meaning of Section 409A of the Code, and the Executive is a specified employee (within the meaning of Section 409A of the Code) as of the date of the Executive’s separation from service, each such
payment that is payable upon the Executive’s separation from service and would have been paid prior to the six-month anniversary of the Executive’s separation from service, shall be delayed until the
earlier to occur of (i) the first day of the seventh month following the Executive’s separation from service or (ii) the date of the Executive’s death. Any reimbursement payable to the Executive pursuant to this Agreement shall
be conditioned on the submission by the Executive of all expense reports reasonably required by the Company under any applicable expense reimbursement policy, and shall be paid to the Executive in accordance with the Company’s expense
reimbursement policy, but in no event later than the last day of the calendar year following the calendar year in which the Executive incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other
calendar year. The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit. 

12. Notices. 
 (a) For
purposes of this Agreement, all notices and other communications required or permitted hereunder must be in writing and will be deemed to have been duly given: (a) when delivered personally to the recipient; (b) two business days after
being sent to the recipient by reputable international overnight courier service (charges prepaid); or (c) on the date sent by facsimile transmission or electronic mail if sent during normal business hours of the recipient, and on the next
business day if sent after normal business hours of the recipient, addressed: (i) if to the Executive, to the home address of the Executive on the most current 

  
 6 

 
Company records; (ii) if to the Company, to RTI Surgical, Inc., 520 Lake Cook Road, Suite 315, Deerfield, Illinois 60015; or (iii) to any other address that either party may have
furnished to the other in writing in accordance with the notice requirements of this Section 12 (provided that such notice has been received by the other party). 

(b) A written notice of the Executive’s Termination Date by the Company or the Executive to the other must (i) indicate the
specific provision in this Agreement applicable to such termination; (ii) to the extent applicable, set forth in reasonable detail the facts and circumstances claimed to provide a basis for the application of such provision to the termination
of the Executive’s employment; and (iii) specify the Termination Date. The failure by the Executive or the Company to set forth in such notice any fact or circumstance that contributes to a showing of Good Reason or Cause will not waive
any right of the Executive or the Company hereunder or preclude the Executive or the Company from asserting such fact or circumstance in enforcing the Executive’s or the Company’s rights hereunder. 

13. Mitigation and Offset; Attorneys’ Fees and Expenses. 

(a) The Company’s obligation to make any payments provided in this Agreement and otherwise to perform its obligations hereunder will not
be affected by any set-off, counterclaim, recoupment, defense, or other claim, right, or action that the Company may have against the Executive or others, except as provided in Section 3(a) or
Section 14. In no event will the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under this Agreement, except as provided in Section 3(a), and such
amounts will not be reduced whether or not the Executive obtains other employment. 
 (b) The Company and the Executive shall each bear
their own attorney’s fees and expenses incurred in connection with any claim or dispute between them relating to or arising out of this Agreement. 

14. Clawback Policy. Notwithstanding anything to the contrary herein, all incentive compensation paid to the Executive in connection
with the Executive’s employment with the Company will be subject to forfeiture, recovery by Company, or other action pursuant to any clawback or recoupment policy that the Company may adopt to the extent the Board determines in its sole
discretion that the adoption and maintenance of such policy is necessary to comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules and regulations thereunder, or is otherwise required by applicable law. 

15. Governing Law; Validity. The interpretation, construction and performance of this Agreement will be governed by and construed and
enforced in accordance with the internal laws of the State of Delaware without regard to the principle of conflicts of laws. The invalidity or unenforceability of any provision of this Agreement will not affect the validity or enforceability of any
other provisions of this Agreement, which other provisions will remain in full force and effect. 
 16. Counterparts. This Agreement
may be executed in two counterparts (including by means of facsimile transmission or electronic mail), each of which will be deemed to be an original and both of which together will constitute one and the same instrument. A manual signature on this
Agreement, an image of which shall have been transmitted electronically, will constitute an original signature for all purposes. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 7 

 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by a duly
authorized officer, and the Executive has executed this Agreement effective as of the day and year first above written. 
  

					
	RTI SURGICAL HOLDINGS, INC.
			
	By:	 	 	 	 
		 	Name: Camille I. Farhat
		 	Title: President and Chief Executive Officer
	
	EXECUTIVE
	
	 
	 Olivier M. Visa

 [Signature Page to Involuntary Termination Agreement]EX-10.50

 Exhibit 10.50 

CONSULTANT AGREEMENT 
 This
CONSULTANT AGREEMENT (the “Agreement”), effective on the 9th day of April 2020 (the “Effective Date”), is by and between Wynand Louw an individual whose address is __________________________ (“Consultant”) and
RTI Surgical Holdings, Inc., a Delaware corporation with a principal address 520 Lake Cook Road, Deerfield, IL 60015 (“RTI”) (each individually a “Party”, and collectively “the Parties”). 

WHEREAS, RTI is a global surgical implant company that provides surgeons with biologic, metal and synthetic implants; 

WHEREAS, RTI has determined that it would benefit from the assistance of Consultant, who possesses certain knowledge and expertise as
more fully described herein; and 
 WHEREAS, Consultant wishes to offer such knowledge and expertise to RTI. 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, RTI and Consultant agree as follows: 

1 – CONSULTING MATTERS 

1.1 Consultant shall provide consulting services to RTI (the “Services”) as set forth in Exhibit A (Schedule of Services).
Consultant shall perform the Services in a professional and workmanlike manner and in compliance with all applicable federal, state and local laws, rules and regulations. 

2 – COMPENSATION 

2.1 RTI shall pay to Consultant the following compensation for Services performed hereunder: 

 

	 	2.1.1	 Twenty three thousand seven hundred forty one dollars ($23,741.00) per month, other than travel, engaged in
rendering Services to RTI, based on a 40 hour work week for providing the Services set forth on Schedule A. Any partial month’s service shall be prorated. 

 

	 	2.1.2	 Reimbursement for reasonable and documented
out-of-pocket expenses incurred by Consultant in connection with performance of the Services. 

 

	 	2.1.3	 All Consultant travel plans relating to this Agreement must be
pre-approved by RTI. Consultant will be entitled to reimbursement of actual travel expenses in accordance with RTI’s travel policy in effect at the time of travel. Travel distances less than fifty
(50) miles shall not be eligible for payment or reimbursement. 

 2.2 Consultant shall provide an invoice to RTI
within ten (10) days following the month in which the Services were rendered. The invoice shall at a minimum specify the date(s) on which Services were rendered and a general description of the Services performed on the corresponding date. 

2.3 All undisputed amounts per Consultant’s invoice shall be due and payable net thirty (30)days of RTI’s receipt of the invoice.

  
 Page 1 of 7 

 3 – INTELLECTUAL PROPERTY MATTERS 

3.1 For the purposes of this Agreement, “Work Product” is defined as all work product, deliverables, devices, inventions (whether or
not patentable or reduced to practice), ideas, information and works of authorship (whether in written or other form and whether or not patentable or protectable by copyright), and know-how that have been
discovered, developed or otherwise created by Consultant as a result of performance under this Agreement, or through the use of knowledge or information obtained from RTI under this Agreement or previous employment with RTI (including its
subsidiaries and affiliates). Consultant shall disclose all Work Product to RTI. Work Product comprised of copyrightable works shall be deemed work made for hire for the benefit of RTI. Consultant acknowledges all Work Product, and all associated
patent, copyright, trademark, trade secret and other intellectual property rights embodied in such Work Product, or otherwise created by Consultant in the course of performing hereunder (“IP Rights”), shall be the exclusive property of
RTI. Consultant further acknowledges and agrees that RTI may, in its sole discretion, create derivative works from such Work Product, including, but not limited to, audio recordings, audiovisual recordings or any other form of derivative work in
which such Work Product may be recast, transformed or adapted. Such derivative works shall also be the exclusive property of RTI. Consultant is not granted any rights, whether expressly, implied or by estoppel, to such Work Product, derivative works
or IP Rights. To the extent exclusive right, title and interest in and to such Work Product, derivative works and IP Rights do not reside exclusively with RTI by operation of law or this Agreement, Consultant agrees to and hereby does assign to RTI
all right, title and interest in and to such Work Product, derivative works and [P Rights. To the extent such Work Product, derivative works and/or IP Rights cannot be assigned to RTI, Consultant agrees to and hereby does waive all rights of
Consultant in and to such Work Product, derivative works and IP Rights. Consultant will cooperate with all requests of RTI to perfect the assignments and waivers set forth in this Section, including cooperation in the form of execution and filing of
additional assignment documents and patent applications. 
 3.1.1 Consultant represents and warrants that all Work Product shall be the
original work of Consultant and that such Work Product, and Consultant’s provision of the Services hereunder, do not infringe or misappropriate the intellectual property rights of any third party. 

3.2 During the term of this Agreement, as may be extended, and for a period of five (5) years following the termination or expiration of
this Agreement (the “Confidentiality Period”), Consultant agrees to keep in confidence and not use any Confidential Information in any manner whatsoever, other than for the sole purpose of assisting RTI pursuant to this Agreement.
Notwithstanding the foregoing, Confidential Information designated in writing as “trade secret” shall be deemed by RTI, in its sole discretion, to have competitively sensitive value beyond the Confidentiality Period and shall be maintained
as confidential by Consultant under the terms of this Agreement for so long as the Confidential Information so designated continues to be a trade secret, as that term is defined by the Uniform Trade Secret Act, drafted by the National Conference of
Commissioners on Uniform State Laws, as amended 1985. Without limiting the generality of the foregoing, Consultant shall not use any Confidential Information for the purposes of trading securities. As used in this Agreement, “Confidential
Information” means any legal, financial or strategic information relating to the Company, the Work Product, as well as RTI’s trade secrets, formulas, processes, methods, know-how and other
information related to biologic, metal and synthetic implants including, but not limited to, allograft and xenograft tissue grafts, and associated patents and patent applications, inventions, surgical instruments, technical data, drawings or
specifications, testing and/or production methods, business or financial information, research and development activities, product and marketing plans, donor information, medical records, and customer and supplier information, which is proprietary
and of a confidential nature, and when furnished, shown or disclosed to Consultant is specifically designated in writing or orally as “confidential”, or which is of such nature and character that a reasonable person in the trade would
understand the information to be confidential without the necessity of it being so designated. The obligations of Consultant under this Section 3 shall survive expiration or termination of this Agreement. 

  
 Page 2 of 7 

 3.3 Consultant shall not disclose, publish, communicate, or reveal RTI’s Confidential
Information to any third party unless: 
  

	 	a.	 express prior written permission is given by RTI and only after such third party executes an agreement with
contractual obligations of confidentiality and non-use with respect to such Confidential Information that are at least as protective as those contained in this Agreement, and provided that Consultant remains
ultimately responsible for such third party’s acts and omissions with respect to such Confidential Information; or 

  

	 	b.	 in the event Confidential Information is required to be disclosed to comply with applicable laws, with a
subpoena, or with a court or administrative order, Consultant shall (i) provide RTI with immediate notice upon learning that such disclosure is required, (ii) use best efforts to assist RTI in taking all reasonable and lawful actions as
deemed prudent by RTI to obtain confidential treatment for the Confidential Information for which disclosure is sought, and (iii) minimize the extent of such disclosure. 

3.4 The provisions of this Agreement regarding confidentiality and non-use of Confidential Information
will not apply to, and Confidential Information does not include, information which: 
  

	 	a.	 was independently developed or discovered by Consultant without use or benefit of RTI’s Confidential
Information, as demonstrated by Consultant’s written records; 

  

	 	b.	 is already available to the public; 

 

	 	c.	 becomes available to the public through no fault of the Consultant; 

 

	 	d.	 is provided to Consultant without obligations of confidentiality and
non-use by a third party having the right to so provide such information. 

 Notwithstanding
anything herein to the contrary, Consultant shall remain bound to any and all obligations of confidentiality for any knowledge gained under previous employment with RTI or its subsidiaries or affiliates, but such information shall nevertheless
constitute Confidential Information for purposes of this Agreement. 
 3.5 Upon the termination or expiration of this Agreement, or within
ten (10) days from receipt of request by RTI, unless otherwise required by law, Consultant shall return to RTI all originals, copies, and summaries of documents, material, and other tangible manifestations of Work Product and Confidential
Information in the possession or control of Consultant, and destroy all intangible manifestations thereof (e.g., electronic files). The obligation of Consultant to return Work Product and Confidential Information to RTI and to destroy intangible
manifestations thereof shall survive until fulfilled. 
 3.6 Consultant acknowledges that RTI is a global surgical implant company providing
surgeons with safe biologic, metal and synthetic implants and stipulates that the restrictions set forth herein are necessary to protect the legitimate business interests of RTI in guarding trade secrets and patentable subject matter, preserving the
goodwill of its customers and business, preventing solicitation of its customers, and preventing the unauthorized use of its Confidential Information and the Work Product created hereunder. 

  
 Page 3 of 7 

 4 – TERM AND TERMINATION 

4.1 Unless otherwise terminated early as set forth in Section 4.2 herein, the term of this Agreement shall commence on the Effective Date
and continue until the earlier of (i) the consummation of the sale of the Company’s OEM business pursuant to the Equity Purchase Agreement dated January 13, 2020 between the Company and affiliates of Montagu Private Equity, and
(ii) the termination of such agreement. 
 4.2 Either Party hereto may terminate this Agreement at any time, with or without cause, by
providing the other Party with thirty (30) days’ advance written notice. 
 5 – GENERAL PROVISIONS 

5.1 Consultant represents and warrants that Consultant is not cognizant of any issues that would be a conflict of interest with the terms and
provisions of this Agreement or Consultant’s performance hereunder. In the event RTI or Consultant identifies a conflict of interest issue, the identifying Party will immediately notify the other Party in writing, and the Parties will work
together to rectify the conflict of interest issue. Any such conflict of interest shall be resolved to the satisfaction of RTI within forty-eight (48) hours of such notice, or this Agreement is otherwise immediately terminable by RTI in its
sole discretion. 
 5.2 This Agreement may not be transferred or assigned by the Consultant, in whole or in part, except with the prior
written consent of RTI. RTI may in its sole discretion assign this Agreement or its rights hereunder. 
 5.3 This Agreement is governed by
and shall be construed and enforced in accordance with the laws of the State of Florida, without regard to conflict of law rules. Venue for any legal proceeding or action at equity or law arising out of or for purposes of this Agreement shall lie in
the state courts of Alachua County, Florida, or the United States District Court for the Northern District of Florida, Gainesville Division, and Consultant agrees that such courts shall have personal jurisdiction over Consultant and hereby waives
any objection thereto. The prevailing Party in any dispute arising under, out of, or in relation to this Agreement shall be entitled to recover reasonable attorneys’ fees and costs from the non-prevailing
Party, including, as applicable, any cost of appeal. 
 5.4 Nothing in this Agreement shall be construed as granting by implication,
estoppel, or otherwise, any license or rights under patents, trade secrets, know-how, copyrights, or other intangible rights of RTI other than those specifically set forth herein. 

5.5 The Parties do not intend that this Agreement shall confer on any third party any right, remedy or benefit or that any third party shall
have any right to enforce any provision of this Agreement. 
 5.6 OTHER THAN ANY WARRANTY EXPRESSLY MADE IN THIS AGREEMENT, RTI MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, IN NO EVENT
SHALL (A) RTI BE LIABLE HEREUNDER FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, REGARDLESS OF WHETHER RTI KNEW OF THE POSSIBILITY OF SUCH DAMAGES; OR (B) RTI’S AGGREGATE LIABILITY HEREUNDER EXCEED THE
AMOUNTS ACTUALLY PAID BY RTI TO CONSULTANT HEREUNDER. 

  
 Page 4 of 7 

 5.7 The right of either Party to terminate this Agreement, as provided under Section 4
herein, shall not be an exclusive remedy, and either Party shall be entitled, if the circumstances warrant, alternatively or cumulatively, to damages for breach of this Agreement, or to an order or injunction requiring performance of the obligations
of this Agreement or to any other remedy available at law or equity. 
 5.8 This Agreement constitutes the entire agreement and
understanding of the Parties with regard to the Consultancy services provided by Consultant and supersedes all prior discussions, negotiations, understandings and agreements between the Parties concerning the subject matter hereof; provided,
however, that any NDA, or confidentiality agreement or policy previously in effect, including Article X of the Amended and Restated Bylaws of RTI Surgical Holdings, Inc., effective March 8, 2019, will remain in effect. 

5.9 This Agreement may be amended only by written agreement of the Parties hereto. 

5.10 If any term of this Agreement is held by a court of competent jurisdiction to be invalid or unenforceable, then this Agreement, including
all of the remaining terms, will remain in full force and effect as if such invalid or unenforceable term had never been included. 
 5.11
In the event any portion of this Agreement may be deemed less stringent than applicable laws, regulations, or official guidance from an applicable governmental authority, the Parties agrees to confer and negotiate in good faith to amend this
Agreement to comply with the more stringent standard. 
 5.12 Each Party to this Agreement hereby agrees to execute, acknowledge and deliver
all such further instruments as may be necessary or appropriate to carry out the intent and purposes of this Agreement. 
 5.13 The headings
contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 

5.14 Neither party shall be responsible or liable to the other party for nonperformance or delay in performance of any terms or conditions of
this Agreement, except for those relative to the protection of proprietary rights, due to circumstances beyond the control of the nonperforming or delaying party including, but not limited to, acts of God, acts of government, wars, riots, third
party criminal acts, strikes or other labor disputes, shortages of labor or materials, fires and floods; provided the nonperforming or delaying party provides to the other party written notice of the existence and reason for such nonperformance or
delay. Notwithstanding the foregoing, the nonperformance or delay by any party in excess of thirty (30) days shall constitute cause for termination of this Agreement with such notice given in writing by one Party to the other. 

  
 Page 5 of 7 

 5.15 Any notice required under this Agreement shall be in writing and delivered to
Consultant at his/her last known address on file with the Company and to RTI as follows: 
  

			
	 RTI:
	  	With copy to:
		
	 RTI Surgical Holdings, Inc. 
520 Lake Cook Road 
Deerfield, IL 60015 
Attn: Chief Financial and Administrative
Officer
	  	RTI Surgical Holdings, Inc. 
11621 Research Circle 
Alachua, FL 32615 
Attn: General Counsel

 All notices shall be deemed duly served on the date delivered to the other Party at the address stated above, whether in
person, sent by certified mail, postage prepaid, return receipt requested, or sent by Federal Express (or other similar recognized courier) postage prepaid. Either Party may change its address for purposes of this Agreement by giving the other Party
written notice of such as provided herein. 
 5.16 RTI and Consultant each acknowledge that they are independent contractors with regard to
the subject matter hereof. Nothing in this Agreement shall be interpreted or construed as creating or establishing the relationship of employer and employee between RTI and Consultant. Both Parties acknowledge that Consultant is not an employee of
RTI for state or federal tax purposes, workers’ compensation, or any other purpose or benefit. Neither Consultant nor RTI shall have any right to enter into any contract or commitment in the name of, or on behalf of the other, or to bind the
other in any respect whatsoever. 
 5.17 Notwithstanding any other provision of this Agreement, Consultant shall not be held criminally or
civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made: (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and
(2) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. Notwithstanding any other provision of this
Agreement, if Consultant files a lawsuit for retaliation by RTI for Consultant’s reporting a suspected violation of law, Consultant may disclose a trade secret to Consultant’s attorney and use the trade secret information in the court
proceeding if Consultant: (a) files any document containing the trade secret under seal; and (b) does not disclose the trade secret, except pursuant to court order. 

5.18 This Agreement may be executed in several counterparts, each of which shall be deemed an original, and all of which taken together shall
constitute but one and the same instrument. 
 5.19 The provisions of this Agreement that, by their sense and context, are intended to
survive the termination or expiration of this Agreement shall so survive the termination or expiration, including, without limitation, the provisions regarding confidentiality, warranty, limitation of liability, notice and the obligation to make any
and all payments due hereunder. 

  
 Page 6 of 7 

 IN WITNESS WHEREOF, the Parties have caused this instrument to be executed. 

 

									
	Wynand Louw	 		 	RTI Surgical, Inc.
					
	Signature:	 	  
	 		 	By:	 	  

		 		 		 	Name:	 	  

		 		 		 	Title:	 	  

	Date:	 	  
	 		 	Date:	 	  

 EXHIBIT A 

Schedule of Services 
  

	1.	 Assisting the Company with matters related to the separation of the OEM and Spine businesses in preparation for
sale of the OEM business to a third party 

  

	2.	 Assisting with matters related to the Coronavirus/COVID — 19 outbreak 

 

	3.	 Assisting the Company with other matters reasonably assigned by the Chief Financial and Administrative Officer

  
 Page 7 of 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]